ALNYLAM PHARMACEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Oct 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 30, 2025
ALNY$155.94-0.5%Stored close · as of Nov 6, 2026
Contents
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $127,328 | $(194,394) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Depreciation and amortization | 42,152 | 42,502 |
| Non-cash interest expense on liability related to the sale of future royalties | 112,298 | 91,834 |
| Stock-based compensation expense | 276,603 | 180,439 |
| Realized and unrealized loss on marketable equity securities | 2,306 | 2,856 |
| Loss on extinguishment of debt | 39,146 | — |
| Change in fair value of development derivative liability | 138,813 | 100,499 |
| Deferred income taxes | 24,972 | 631 |
| Other | (31,464) | (32,228) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (544,210) | (27,042) |
| Inventory | 22,335 | 12,741 |
| Prepaid expenses and other assets | (46,734) | (22,052) |
| Accounts payable, accrued expenses and other liabilities | 249,920 | 153,200 |
| Deferred revenue | (52,940) | (222,636) |
| Net cash provided by operating activities | 360,525 | 86,350 |
| Cash flows from investing activities: | ||
| Purchases of property, plant and equipment | (35,405) | (25,183) |
| Purchases of marketable securities | (1,069,170) | (1,148,203) |
| Sales and maturities of marketable securities | 1,580,220 | 1,128,656 |
| Proceeds from maturity of restricted investments | 59,775 | 57,875 |
| Purchases of restricted investments | (59,775) | (77,075) |
| Other investing activities | (2,150) | — |
| Net cash provided by (used in) investing activities | 473,495 | (63,930) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of 0.00% Convertible Senior Notes due 2028, net | 646,372 | — |
| Purchases of capped calls related to 0.00% Convertible Senior Notes due 2028 | (35,311) | — |
| Repayment of 1.00% Convertible Senior Notes due 2027 | (1,102,659) | — |
| Payment of issuance costs for revolving credit agreement | (2,414) | — |
| Proceeds from exercise of stock options and other types of equity, net | 208,327 | 266,673 |
| (Repayment of) proceeds from development derivative, net | (64,822) | (3,511) |
| Net cash used in (provided by) financing activities | (350,507) | 263,162 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 40,637 | 2,032 |
| Net increase in cash, cash equivalents and restricted cash | 524,150 | 287,614 |
| Cash, cash equivalents and restricted cash, beginning of period | 968,652 | 814,884 |
| Cash, cash equivalents and restricted cash, end of period | $1,492,802 | $1,102,498 |
| Supplemental disclosure of cash flows: | ||
| Cash paid for interest | $105,390 | $55,248 |
| Cash paid for taxes | $2,375 | $8,168 |
| Operating lease right-of-use assets obtained in exchange for new operating lease liabilities | $12,379 | $9,732 |
| Supplemental disclosure of noncash investing activities: | ||
| Capital expenditures included in accounts payable and accrued expenses | $9,604 | $742 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.